Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information

v3.8.0.1
Note 11 - Segment Information
 9 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note
11.
Segment Information:
 
The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses.
 
The following is financial information relating to the Company's reportable segments (in thousands):
 
   
Quarter Ended
    
Nine Months Ended
  
   
March 31,
    
March 31,
  
   
2018
    
2017
    
2018
    
2017
  
Net sales:
                                
Biotechnology
   $
110,029
     $
94,516
     $
306,516
     $
267,256
  
Protein Platforms
    
25,539
      
23,586
      
79,566
      
64,707
  
Diagnostics
    
28,548
      
25,978
      
76,963
      
74,542
  
Intersegment
    
(143
)
    
(43
)
    
(306
)
    
(80
)
Consolidated net sales
   $
163,973
     $
144,037
     $
462,739
     $
406,425
  
Operating income:
                                
Biotechnology
   $
53,013
     $
45,242
     $
143,826
     $
127,195
  
Protein Platforms
    
2,461
      
3,256
      
11,636
      
5,308
  
Diagnostics
    
7,988
      
6,004
      
17,594
      
18,108
  
Segment operating income
   $
63,462
     $
54,502
     $
173,056
     $
150,611
  
Costs recognized on sale of acquired inventory
    
(1,431
)
    
(637
)
    
(2,013
)
    
(2,770
)
Amortization of acquisition related intangible assets
    
(11,872
)
    
(11,689
)
    
(34,547
)
    
(33,504
)
Acquisition related expenses
    
(1,312
)
    
(3,993
)
    
(23,994
)
    
(19,581
)
Stock based compensation
    
(4,748
)
    
(3,974
)
    
(13,587
)
    
(11,219
)
Corporate general, selling, and administrative expenses
    
(1,015
)
    
(707
)
    
(5,652
)
    
(2,999
)
Consolidated operating income
   $
43,084
     $
33,502
     $
93,263
     $
80,538